CompletedNot Applicable

Determining Prevalence of Acute Bilirubin Encephalopathy in Developing Countries

Nigeria624 participantsStarted 2012-12

Plain-language summary

The investigators hypothesize that a new BIND (Bilirubin Induced Neurologic Dysfunction) scoring method adapted for the developing world (BIND II, developed by our team for use by health care workers), with additional modifications for community use (the community BIND, C-BIND), will improve the ability to identify infants with ABE and to distinguish ABE from other common causes of neonatal morbidity and mortality compared to currently available survey tools.

Who can participate

Age range14 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. At time of birth, neonates who are ≥ 35 weeks gestational age or
✓. ≤ 14 days old
✓. Parent or guardian has given consent for the infant to participate

Exclusion criteria

✕. Infants with a condition requiring urgent referral to another facility for treatment not available at the hospital study site.
✕. Infants being admitted for a surgical procedure only without an underlying medical illness.
✕. Infants who have a condition that requires no blood draws for treatment of their problem and only reason for blood draw would be study enrollment. -

What they're measuring

Bilirubin Induced Neurologic Dysfunction II Score (BIND II)

Timeframe: Birth to 14 days

Trial details

NCT IDNCT01754688

SponsorUniversity of Minnesota

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2015-02

Results submitted2016-07-27

View on ClinicalTrials.gov More Hyperbilirubinemic Encephalopathy trials